Oncology drug discovery faces one of the highest attrition rates for drug candidates in the
development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression,
could address this problem.
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.